The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients

Cellular Immunology

Volumn 294, Issue 1, 2015, Pages 9-12

  Najafipoor, Adeleh ^a   Roghanian, Rasoul ^a   Zarkesh Esfahani, Sayyed Hamid ^a,b   Bouzari, Majid ^a   Etemadifar, Masoud ^c,d  

^a UNIVERSITY OF ISFAHAN   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Isfahan Research Committee of Multiple Sclerosis (IRCOMS)   (Iran)

Author keywords

25 Hydroxyvitamin D (25OHD); Epstein Barr nuclear antigen 1 (EBNA1); Epstein Barr virus (EBV); Immune modulation; Multiple sclerosis (MS); Viral capsid antigen (VCA)

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; IMMUNOGLOBULIN G; VIRUS CAPSID ANTIGEN; 25-HYDROXYVITAMIN D; CAPSID PROTEIN; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN-BARR VIRAL CAPSID ANTIGEN; VIRUS ANTIBODY; VIRUS ANTIGEN; VITAMIN D;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLOOD; DIET SUPPLEMENTATION; DRUG EFFECTS; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

HUMAN HERPESVIRUS 4; MIRIDAE;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; MALE; MULTIPLE SCLEROSIS; VITAMIN D;

EID: 84923052757     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.01.009     Document Type: Article

References (41)

1. Bernard C.C., De Rosbo N.K. Multiple sclerosis: an autoimmune disease of multifactorial etiology. Curr. Opin. Immunol. 1992, 4(6):760-765.
2. Decard B.F., Ahsen N.V., Grunwald T., et al. Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2012, 83(12):1170-1174.
3. Disanto G., Handel A.E., Damoiseaux J., et al. Vitamin D supplementation and antibodies against the Epstein-Barr virus in multiple sclerosis patients. Mult. Scler. 2013, 19(12):1679-1680.
4. Disanto G., Meier U., Giovannoni G., Ramagopalan S.V. Vitamin D: a link between Epstein-Barr virus and multiple sclerosis development. Expert Rev. Neurother. 2011, 11(9):1221-1224.
5. Holmoy T. Vitamin D status modulates the immune response to Epstein Barr virus: synergistic effect of risk factors in multiple sclerosis. Med. Hypotheses 2007, 70(1):66-69.
6. Salzer J., Nyström M., Hallmans G., Stenlund H., Wadell G., Sundström P. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples. Mult. Scler. 2013, 19(12):1587-1591.
7. Wingerchuk D.M. Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking. Mt Sinai J. Med. 2011, 78(2):221-230.
8. Almohmeed Y.H., Avenell A., Aucott L., Vickers M.A. Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. PLoS ONE 2013, 8(4):e61110.
9. Ascherio A., Munger K.L., Lennette E.T., et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001, 286(24):3083-3088.
10. Lünemann J.D., Edwards N., Muraro P.A., et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006, 129(Pt. 6):1493-1506.
11. Lünemann J.D., Tintoré M., Messmer B., et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 2010, 67(2):159-169.
12. Sundqvist E., Sundström P., Lindén M., et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun. 2012, 13(1):14-20.
13. Sundstrom P., Juto P., Wadell G., et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004, 62(12):2277-2282.
14. Yea C., Tellier R., Chong P., et al. Epstein-Barr virus in oral shedding of children with multiple sclerosis. Neurology 2013, 81(16):1392-1399.
15. Ascherio A., Munger K.L. Epstein Barr virus infection and multiple sclerosis. J. Neuroimmune Pharmacol. 2010, 5(3):271-277.
16. Buljevac D., van Doornum G.J., Flach H.Z., et al. Epstein-Barr virus and disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2005, 76(10):1377-1381.
17. Munch M., Hvas J., Christensen T., Møller-Larsen A., Haahr S. The implications of Epstein-Barr virus in multiple sclerosis - a review. Acta Neurol. Scand. Suppl. 1997, 169:59-64.
18. Shirodaria P.V., Haire M., Fleming E., Merrett J.D., Hawkins S.A., Roberts S.D. Viral antibody titers: comparison in patients with multiple sclerosis and rheumatoid arthritis. Arch. Neurol. 1987, 44(12):1237-1241.
19. Salzer J., Hallmans G., Nyström M., Stenlund H., Wadell G., Sundström P. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012, 79(21):2140-2145.
20. Mei I.A.F., Ponsonby A.L., Dwyer T., et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol. 2007, 254(5):581-590.
21. Correale J., Ysrraelit M.C., Gaitan M.I. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009, 132(Pt. 5):1146-1160.
22. Beard J.A., Bearden A., Striker R. Vitamin D and the anti-viral state. J. Clin. Virol. 2011, 50(3):194-200.
23. Gabibov A.G., Belogurov A.A., Lomakin Y.A., et al. Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross-react with myelin basic protein and EBV antigen. FASEB J. 2011, 25(12):4211-4221.
24. Rand K.H., Houck H., Denslow N.D., Heilman K.M. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J. Neurol. Sci. 2000, 173(1):32-39.
25. Vaughan J.H., Riise T., Rhodes G.H., Nguyen M.D., Barrett-Connor E., Nyland H. An Epstein Barr virus-related cross reactive autoimmune response in multiple sclerosis in Norway. J. Neuroimmunol. 1996, 69(1-2):95-102.
26. Mowry E.M., James J.A., Krupp L.B., Waubant E. Vitamin D status and antibody levels to common viruses in pediatric-onset multiple sclerosis. Mult. Scler. 2011, 17(6):666-671.
27. Polman C.H., Reingold S.C., Banwell B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69(2):292-302.
28. DeLorenze G.N., Munger K.L., Lennette E.T., Orentreich N., Vogelman J.H., Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 2006, 63(6):839-844.
29. Simon K.C., O'Reilly E.J., Munger K.L., Finerty S., Morgan A.J., Ascherio A. Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis. Mult. Scler. 2012, 18(8):1185-1187.
30. Adams J., Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4(2):80-90.
31. Di Rosa M., Malaguarnera M., Nicoletti F., Malaguarnera L. Vitamin D3: a helpful immuno-modulator. Immunology 2011, 134(2):123-139.
32. Baeke F., Takiishi T., Korf H., Gysemans C., Mathieu C. Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 2010, 10(4):482-496.
33. Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann. N.Y. Acad. Sci. 2003, 987:258-261.
34. Adorini L., Giarratana N., Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Sem. Immunol. 2004, 16(2):127-134.
35. Piemonti L., Monti P., Sironi M., et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J. Immunol. 2000, 164(9):4443-4451.
36. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1.25 dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179(3):1634-1647.
37. Smolders J., Thewissen M., Peelen E., et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS ONE 2009, 4(8):e6635. 10.1371/journal.pone.0006635.
38. Wingate P.J., McAulay K.A., Anthony I.C., Crawford D.H. Regulatory T cell activity in primary and persistent Epstein-Barr virus infection. J. Med. Virol. 2009, 81(5):870-877.
39. Yenamandra S.P., Hellman U., Kempkes B., et al. Epstein-Barr virus encoded EBNA-3 binds to vitamin D receptor and blocks activation of its target genes. Cell. Mol. Life Sci. 2010, 67(24):4249-4256.
40. Zwart S.R., Mehta S.K., Ploutz-Snyder R., et al. Response to vitamin D supplementation during antarctic winter is related to BMI, and supplementation can mitigate Epstein-Barr virus reactivation. J. Nutr. 2011, 141(4):692-697.
41. Ramien C., Pachnio A., Sisay S., et al. Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort. Mult. Scler. 2013, 1-3.